Each color describes the location of the peptide (Table 4)

Each color describes the location of the peptide (Table 4). and chain ARRY-543 (Varlitinib, ASLAN001) 42-56 (with highest bepipred score: 0.58) named as peptide2. In western blotting test, both antibodies showed detection at 47kDa. When examined with western blot using ARRY-543 (Varlitinib, ASLAN001) urine from BC patients, urine from other cancer patients (prostate, kidney, ureter, rectal, breast), and healthy persons, both antibodies were found to only express 47kDa in urine from BC patients. The diagnostic assessments showed high sensitivity (91.67%) and specificity (94.44%) inAb2 in predicting bladder malignancy. == Conclussion: == The development of the polyclonal antibody made from specific epitopes is proven to express specifically on bladder malignancy patients and have high sensitivity and specificity to diagnose bladder malignancy. Key Words:Bladder malignancy, diagnosis, Epitopes, 47 kDa Protein == Introduction == Bladder malignancy is the ninth-leading cause of malignancy in the world. To date, there have been 430,000 people diagnosed with bladder malignancy (Redondo-Gonzalez et al., 2015). Bladder malignancy is one of the malignancies that occur in the urinary tract. The most frequent type of bladder malignancy is usually transitional cell carcinoma (TCC), which starts in the cells that form the epithelial lining of the bladder (Wong et al., 2018). The main problem is the lack of accessible simple diagnostic tools that medical professionals in remote areas can use to diagnose BC. Another factor associated with bladder malignancy is the high recurrence rate, i.e., 5070% of newly diagnosed tumors recur within five years, and progression to an invasive disease will occur in 1020% of patients. Therefore, patients with bladder malignancy should undergo life-long surveillance (van Rhijn et al., 2014). Proteomics is one of the fastest-growing fields of molecular biology and is concerned with an experimental approach using in-silico study to analyze protein expression in cells or organisms by protein isolation and sequencing (Prasetya et al., 2014). In a previous preliminary study, it was found that a protein with a molecular excess weight of 122 kDa was found in normal bladder epithelial cells and malignancy cells in the bladder (Ladner, 2007). In comparison, a protein with a molecular excess weight of 69 kDa was only ARRY-543 (Varlitinib, ASLAN001) found in normal bladder epithelial cells. In addition, a protein with a molecular excess weight of 47 kDa was only found in bladder malignancy cells (Ladner, 2007). The sensitivity value of the immunocytochemical examination using a 47 kDa polyclonal antibody from bladder malignancy epithelial cells was 100%, while the specificity was 30%. The sensitivity value of polyclonal antibody of 47 kDA were higher than bladder tumor antigen STAT (BTA-STAT), urinary bladder malignancy rapid (UBC Rapid), bladder tumor antigen – TRAK assay (BTA -TRAK), Urinary Bladder Malignancy Rapid – immunoradioassay (UBC IRMA). (Table 1) Nuclear matrix protease-22 (NMP-22) and telomeric repeat amplification protocol (TRAP) were thought to be based on the characteristics of the targeted antigen (Larsen et al., 2006; Proctor et al., 2010; Nugraha, 2011). Alternatively, to increase the specificity of 47 kDa antibodies, they are made using specific epitopes. == Table 1. == Keratin sequence, type I cytoskeletal, red color shows the 47kDA protein sequence obtained from the urine of Protein Rabbit Polyclonal to NCAML1 Carcinoma Bladder The epitope is usually a particular area in the antigen where the specific antibody binds. This bond will initiate the specific immune response (Nugraha, 2011). In previous research for examining polyclonal antibodies against the 47kDa protein, there was still no identification of specific epitopes that were specifically expressed in bladder malignancy patients (Ladner, 2007); hence this study was conducted to identify specific epitopes around the 47kDa protein as the basis for making antibodies for bladder malignancy biomarkers. The concern is usually that 47 kDa protein is a foreign protein produced by bladder malignancy cells that is not generally expressed by normal bladder epithelial cells. == Materials and Methods.